Ovarian Cancer Immunotherapy: Opportunities, Progresses and Challenges

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2010 Feb 12

PMID 20146807

Citations 31

Authors

Bei Liu

John Nash

Carolyn Runowicz

Helen Swede

Richard Stevens

Zihai Li

Affiliations

Soon will be listed here.

Abstract

Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.

Citing Articles

The Role of the Plasminogen Activator Inhibitor 1 ( ) in Ovarian Cancer: Mechanisms and Therapeutic Implications.

Mathews S, Krishna R, M L, K N, Murali S, Agarwal P Glob Med Genet. 2024; 11(4):358-365.

PMID: 39583124 PMC: 11521755. DOI: 10.1055/s-0044-1791734.

CD4CCR8 Tregs in ovarian cancer: a potential effector Tregs for immune regulation.

Liu S, Tao Z, Lou J, Li R, Fu X, Xu J J Transl Med. 2023; 21(1):803.

PMID: 37950246 PMC: 10638792. DOI: 10.1186/s12967-023-04686-3.

Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Wilczynski J, Nowak M Exp Suppl. 2022; 113:1-57.

PMID: 35165859 DOI: 10.1007/978-3-030-91311-3_1.

Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

ODwyer J, OCearbhaill R, Wylie R, OMahony S, ODwyer M, Duffy G Adv Ther (Weinh). 2021; 3(11).

PMID: 33709016 PMC: 7942751. DOI: 10.1002/adtp.202000144.

microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.

Han F, Li J, Shen Y, Guo Y, Liu Y, Yu Y J Ovarian Res. 2020; 13(1):110.

PMID: 32948241 PMC: 7501628. DOI: 10.1186/s13048-020-00720-w.

References

Yin B, Dnistrian A, Lloyd K . Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002; 98(5):737-40. DOI: 10.1002/ijc.10250. View

Nagaraj S, Gabrilovich D . Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008; 68(8):2561-3. DOI: 10.1158/0008-5472.CAN-07-6229. View

Brossart P, Wirths S, Stuhler G, Reichardt V, Kanz L, Brugger W . Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96(9):3102-8. View

Coley W . The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991; (262):3-11. View

Hird V, Maraveyas A, Snook D, Dhokia B, Soutter W, Meares C . Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993; 68(2):403-6. PMC: 1968585. DOI: 10.1038/bjc.1993.349. View

Noujaim A, Schultes B, Baum R, Madiyalakan R . Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm. 2001; 16(3):187-203. DOI: 10.1089/10849780152389384. View

Tomsova M, Melichar B, Sedlakova I, Steiner I . Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol. 2007; 108(2):415-20. DOI: 10.1016/j.ygyno.2007.10.016. View

Rosenblum M, Verschraegen C, Murray J, Kudelka A, Gano J, Cheung L . Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res. 1999; 5(5):953-61. View

Brune I, Wilke W, Hensler T, Holzmann B, Siewert J . Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg. 1999; 177(1):55-60. DOI: 10.1016/s0002-9610(98)00299-2. View

10.

McAneny D, Ryan C, Beazley R, Kaufman H . Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol. 1996; 3(5):495-500. DOI: 10.1007/BF02305769. View

11.

Berd D, Kairys J, Dunton C, Mastrangelo M, Sato T, MAGUIRE Jr H . Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998; 25(6):646-53. View

12.

Jonasch E, Wood C, Tamboli P, Pagliaro L, Tu S, Kim J . Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008; 98(8):1336-41. PMC: 2361701. DOI: 10.1038/sj.bjc.6604266. View

13.

Sandmaier B, Oparin D, Holmberg L, Reddish M, MacLean G, Longenecker B . Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother. 1999; 22(1):54-66. DOI: 10.1097/00002371-199901000-00008. View

14.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

15.

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

16.

Li Z . Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol. 1997; 9(5):315-22. DOI: 10.1006/smim.1997.0087. View

17.

Cormier J, Salgaller M, Prevette T, Barracchini K, Rivoltini L, Restifo N . Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997; 3(1):37-44. PMC: 2597550. View

18.

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

19.

Chu C, Kim S, June C, Coukos G . Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther. 2008; 8(2):243-57. DOI: 10.1586/14737140.8.2.243. View

20.

Pujade-Lauraine E, Guastalla J, Colombo N, Devillier P, Francois E, Fumoleau P . Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996; 14(2):343-50. DOI: 10.1200/JCO.1996.14.2.343. View